Digoxin, Narrow-Index Oral Drugs, and Practical Timing Digoxin has a narrow therapeutic index (0.5 to 0.9 ng/mL for heart failure, per 2022 AHA/ACC/HFSA guidelines) [20]
Nutritional solutions targeting side effects such as muscle loss and digestive discomfort are in high demand, especially as more consumers turn to GLP-1 medications
PlexusDx removes this barrier with direct-to-patient compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month planno insurance required, no membership fees, and HSA/FSA eligible
And skip the roots, as they contain a toxic compound called spirochin
In this episode, McCall McPherson introduces clinicians Yari Tran, Melody Volz, and Nikki Abelow as they share their journeys into thyroid medicine and explain why personalized care and deeper testing matter
Orforglipron is central to Eli Lillys oral strategy